
Keywords: Steatohepatitis; treatmentASBT, apical sodium-dependent bile acid transporter; CB1, Cannabinoid 1; CCR, chemokine (C-C motif) receptor 2; EPA, eicosapentaenoic acid; FDA, Food and Drug Administration; GLP1, glucagon-like peptide-1; IL, interleukin; LDL, l